RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with TRK fusion cancer, with an objective response rate (ORR) of 78% across multiple non-CNS cancers (McDermott et al, ESMO 2020). We re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Perreault, Sébastien, Doz, François, Geoerger, Birgit, Nysom, Karsten, Øra, Ingrid, Boni, Valentina, Chisholm, Julia, DuBois, Steven G, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Kang, Hyoung Jin, Capra, Michael, Schulte, Johannes H, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Rare Tumors/Other
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168097/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.168
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados